Patents Assigned to Vegenics Limited
-
Publication number: 20120125348Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.Type: ApplicationFiled: October 21, 2011Publication date: May 24, 2012Applicant: VEGENICS LIMITEDInventors: KARI ALITALO, Anne Saaristo, Tuomas Tammela
-
Publication number: 20110269146Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.Type: ApplicationFiled: November 5, 2010Publication date: November 3, 2011Applicant: VEGENICS LIMITEDInventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
-
Publication number: 20110243912Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.Type: ApplicationFiled: December 17, 2010Publication date: October 6, 2011Applicant: VEGENICS LIMITEDInventors: Kari Alitalo, Markku Michael Jeltsch
-
Publication number: 20110189170Abstract: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.Type: ApplicationFiled: December 3, 2010Publication date: August 4, 2011Applicant: VEGENICS LIMITEDInventors: MARC GREGORY ACHEN, STEVEN ALAN STACKER, CHRISTOPH RENNER
-
Publication number: 20110142839Abstract: The invention relates to a method of treatment of pulmonary edema, comprising the step of administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis or inhibiting VEGF-D activity in the subject. The method may comprise the step of identifying a subject at risk of developing pulmonary edema. The invention also relates to an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity for treating pulmonary edema in a subject. Further, the invention relates to use of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity in the manufacture of a medicament for treating pulmonary edema in a subject.Type: ApplicationFiled: May 29, 2009Publication date: June 16, 2011Applicant: Vegenics LimitedInventors: Marc G. Achen, Steven A. Stacker, Teruhiko Sato
-
Patent number: 7947472Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.Type: GrantFiled: December 23, 1998Date of Patent: May 24, 2011Assignee: Vegenics LimitedInventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
-
Publication number: 20110059890Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.Type: ApplicationFiled: October 12, 2009Publication date: March 10, 2011Applicant: VEGENICS LIMITEDInventors: MARC G. ACHEN, STEVEN ALAN STACKER, KARI ALITALO
-
Patent number: 7887800Abstract: Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a pharmaceutical compositions comprising plasmin. Also disclosed are methods of screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-CD, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors.Type: GrantFiled: December 9, 2008Date of Patent: February 15, 2011Assignee: Vegenics LimitedInventors: Bradley McColl, Megan E. Baldwin, Stephen A. Stacker, Marc G. Achen
-
Patent number: 7871798Abstract: Disclosed herein are mammalian cells transformed or transfected with a VEGF-D nucleic acid consisting of a nucleotide sequence encoding continuous portions of VEGF-D polypeptides.Type: GrantFiled: August 23, 2007Date of Patent: January 18, 2011Assignee: Vegenics LimitedInventors: Marc G. Achen, Andrew F. Wilks, Steven Stacker, Kari Alitalo
-
Patent number: 7855178Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.Type: GrantFiled: July 28, 2008Date of Patent: December 21, 2010Assignee: Vegenics LimitedInventors: Kari Alitalo, Markku Michael Jeltsch
-
Patent number: 7846437Abstract: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.Type: GrantFiled: June 30, 2008Date of Patent: December 7, 2010Assignee: Vegenics LimitedInventors: Marc Gregory Achen, Steven Alan Stacker, Christoph Renner
-
Patent number: 7829536Abstract: The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.Type: GrantFiled: February 5, 2009Date of Patent: November 9, 2010Assignees: Vegenics Limited, University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Robert E. Ferrell, Kari Alitalo, David N. Finegold, Marika Karkkainen
-
Patent number: 7829091Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: February 9, 2004Date of Patent: November 9, 2010Assignee: Vegenics LimitedInventor: Kari Alitalo
-
Patent number: 7794756Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.Type: GrantFiled: October 30, 2007Date of Patent: September 14, 2010Assignee: Vegenics LimitedInventors: Kari Alitalo, Vladimir Joukov
-
Patent number: 7785803Abstract: Disclosed herein are VEGF-D antibody diagnostic kits and methods of using such kits for the detection of VEGF-D in a biological sample.Type: GrantFiled: October 30, 2007Date of Patent: August 31, 2010Assignee: Vegenics LimitedInventors: Marc G. Achen, Steven A. Stacker, Kari Alitalo, Andrew F. Wilks
-
Patent number: 7727761Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.Type: GrantFiled: March 3, 2004Date of Patent: June 1, 2010Assignee: Vegenics LimitedInventors: Kari Alitalo, Vladimir Joukov
-
Publication number: 20100041605Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.Type: ApplicationFiled: June 23, 2009Publication date: February 18, 2010Applicant: Vegenics LimitedInventors: Kari Alitalo, Anne Saaristo, Marika Karkkainen, Tuomas Tammela, Sirpa Asko-Seljavaara, Seppo Yla-Herttuala, Yulong He
-
Patent number: 7662932Abstract: The present invention provides VEGF-D polypeptides, which among other things stimulate endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as fragments, dimers, and methods of using the same.Type: GrantFiled: June 29, 2007Date of Patent: February 16, 2010Assignee: Vegenics LimitedInventors: Marc G. Achen, Andrew F. Wilks, Stephen A. Stacker, Kari Alitalo
-
Publication number: 20090318352Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.Type: ApplicationFiled: April 10, 2009Publication date: December 24, 2009Applicant: VEGENICS LIMITEDInventors: Kari Alitalo, Markku Michael Jeltsch
-
Patent number: 7611711Abstract: The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.Type: GrantFiled: January 15, 2002Date of Patent: November 3, 2009Assignee: Vegenics LimitedInventors: Kari Alitalo, Erkki Koivunen, Hajime Kubo